Global Budesonide Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  4.85 billion in 2017, and is projected to exhibit a CAGR of 5.8% over the forecast period (2018 - 2026).

Key players in the market are focused on developing generics version of budesonide inhaler in affordable prices and in various forms such as dry powder, aerosols, suspensions or spray for asthma patients. Increasing number of regulatory approvals for generic versions of budesonide inhaler is a major factor driving growth of the budesonide inhaler market. For instance, in 2018, Lupin received approval for its budesonide inhalation suspension 0.5/2ml single dose ampules from the U.S.FDA to market generic versions AstraZeneca’s Pulmicort Respules. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

Moreover, key manufacturers are also focused on developing new combinations of budesonide inhaler with other drugs to enhance their market share. Budesonide can be made in combination with formoterol. In September 2016, Orion Corporation announced that it has entered into a collaboration agreement with Menarini Group for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal. Budesonide-formoterol Easyhaler is an inhaled combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The product is available under the brand name Bufomix Easyhaler in most of the European countries.

Browse 21 Market Data Tables and 19 Figures spread through 149 Pages and in-depth TOC on "Global Budesonide Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" To know the latest trends and insights related to budesonide inhaler market, click the link below: https://www.coherentmarketinsights.com/market-insight/budesonide-inhaler-market-2551 Key Takeaways of the Budesonide Inhaler Market:

  • The global budesonide inhaler market is expected to witness a CAGR of 5.8% during the forecast period (2018–2026), owing to increasing number of regulatory approvals for generic versions of budesonide inhaler
  • Among product type, the inhalant segment is expected to hold major revenue share in the market over the forecast period.
  • Key players in the market are focused on developing generic versions of budesonide inhaler for asthma and COPD, which is expected to drive growth of the inhalant segment in the market. For instance, in 2017, Cipla Ltd. received final approval for Budesonide Inhalation Suspension, from the U.S. FDA to market a generic version of AstraZeneca's Pulmicort Respules.
  • Major players operating in the global budesonide inhaler market include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner